Compare FMC Corp (FMC) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance

FMC Corporation (FMC) trades at $10.72, down 1.74% on the day, reflecting ongoing challenges despite recent strategic moves. The stock shows a bearish technical trend with oversold RSI signals, while fundamentals reveal significant pressure with a net income margin of -72.93% and negative ROE of -80.78% for 2025. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide rimisoxafen, providing some operational support amid financial restructuring.

The outlook remains cautious with analyst consensus leaning neutral (50% Hold) despite a $16 price target suggesting 49% upside. Key risks include persistent revenue declines, high debt levels, and negative cash flow from operations. Investment opportunity exists if new product approvals and debt reduction efforts successfully stabilize profitability, but current financial metrics indicate substantial execution risk near term.

Dentsply Sirona (XRAY) trades at $12.70, down 0.63% with bearish profitability metrics including negative net income margin and ROE. The stock shows mixed technical signals with bullish moving averages but overbought RSI levels. Recent earnings have consistently missed expectations, though the company maintains a 48.93% gross margin and is expanding its US distribution network with new partnerships and AI-enabled product launches.

While analyst consensus leans Hold with a $13.33 price target, the stock faces significant fundamental challenges including declining revenue, negative earnings, and rising debt-to-asset ratios. Near-term catalysts include the Q2 2026 earnings report and continued execution of the Return-to-Growth plan, but investors should weigh the high valuation multiples against persistent profitability concerns.